MENU
+Compare
ABUS
Stock ticker: NASDAQ
AS OF
Sep 26, 04:59 PM (EDT)
Price
$4.41
Change
+$0.09 (+2.08%)
Capitalization
845.39M

ABUS Arbutus Biopharma Corp Forecast, Technical & Fundamental Analysis

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases... Show more

Industry: #Biotechnology
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ABUS with price predictions
Sep 25, 2025

ABUS's Stochastic Oscillator dives oversold zone

The Stochastic Oscillator for ABUS moved into oversold territory on September 25, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for ABUS moved above the 200-day moving average on September 04, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 227 cases where ABUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ABUS moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on September 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ABUS as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ABUS turned negative on September 19, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ABUS broke above its upper Bollinger Band on September 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.183) is normal, around the industry mean (19.661). P/E Ratio (0.000) is within average values for comparable stocks, (53.961). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.097). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (54.348) is also within normal values, averaging (344.769).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ABUS is expected to report earnings to fall 425.00% to -3 cents per share on November 05

Arbutus Biopharma Corp ABUS Stock Earnings Reports
Q3'25
Est.
$-0.03
Q2'25
Beat
by $0.05
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.02
Q3'24
Missed
by $0.01
The last earnings report on August 06 showed earnings per share of 0 cents, beating the estimate of -3 cents. With 610.89K shares outstanding, the current market capitalization sits at 845.39M.
A.I. Advisor
published General Information

General Information

a developer of drugs to improve the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
701 Veterans Circle
Phone
+1 267 469-0914
Employees
73
Web
http://www.arbutusbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EGOIX20.75N/A
N/A
Allspring Large Cap Core Inst
VSMCX11.01N/A
N/A
Invesco Small Cap Value C
CVLEX15.53N/A
N/A
Cullen Value Retail
NWHQX35.95N/A
N/A
Nationwide Bailard Tech & Sci M
NSRKX25.94N/A
N/A
Northern World Selection Index K

ABUS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+2.08%
IDYA - ABUS
47%
Loosely correlated
+4.52%
BMRN - ABUS
43%
Loosely correlated
+2.32%
ROIV - ABUS
42%
Loosely correlated
+1.47%
TERN - ABUS
41%
Loosely correlated
+2.69%
IMVT - ABUS
40%
Loosely correlated
+3.51%
More